company background image
PCRX

Pacira BioSciencesNasdaqGS:PCRX Stock Report

Last Price

US$63.43

Market Cap

US$2.8b

7D

-1.0%

1Y

-6.5%

Updated

21 Jan, 2022

Data

Company Financials +
PCRX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance2/6
Financial Health5/6
Dividends0/6

PCRX Stock Overview

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States.

Pacira BioSciences Competitors

Pfizer

NYSE:PFE

US$296.3b

Supernus Pharmaceuticals

NasdaqGM:SUPN

US$1.6b

ANI Pharmaceuticals

NasdaqGM:ANIP

US$686.4m

Collegium Pharmaceutical

NasdaqGS:COLL

US$616.3m

Price History & Performance

Summary of all time highs, changes and price drops for Pacira BioSciences
Historical stock prices
Current Share PriceUS$63.43
52 Week HighUS$80.00
52 Week LowUS$45.05
Beta0.99
1 Month Change5.12%
3 Month Change20.57%
1 Year Change-6.53%
3 Year Change63.23%
5 Year Change70.28%
Change since IPO803.56%

Recent News & Updates

Dec 20

Pacira BioSciences: Higher Prices On The Horizon

The company reports an EPS beat of $0.72 in the third quarter. We look into how management has been employing its capital. We like the results as well as the underlying trend. A bullish move through a breakout above the bullish triangle (below) could be on the cards here shortly.

Nov 29
Investors Appear Satisfied With Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Prospects

Investors Appear Satisfied With Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Prospects

With a price-to-earnings (or "P/E") ratio of 37.3x Pacira BioSciences, Inc. ( NASDAQ:PCRX ) may be sending very bearish...

Shareholder Returns

PCRXUS PharmaceuticalsUS Market
7D-1.0%-2.5%-6.1%
1Y-6.5%5.3%4.2%

Return vs Industry: PCRX underperformed the US Pharmaceuticals industry which returned 7.1% over the past year.

Return vs Market: PCRX underperformed the US Market which returned 6.6% over the past year.

Price Volatility

Is PCRX's price volatile compared to industry and market?
PCRX volatility
PCRX Average Weekly Movement4.5%
Pharmaceuticals Industry Average Movement10.5%
Market Average Movement6.7%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.4%

Stable Share Price: PCRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: PCRX's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006624Dave Stackhttps://www.pacira.com

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves.

Pacira BioSciences Fundamentals Summary

How do Pacira BioSciences's earnings and revenue compare to its market cap?
PCRX fundamental statistics
Market CapUS$2.83b
Earnings (TTM)US$61.63m
Revenue (TTM)US$513.31m

45.8x

P/E Ratio

5.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PCRX income statement (TTM)
RevenueUS$513.31m
Cost of RevenueUS$191.91m
Gross ProfitUS$321.41m
ExpensesUS$259.78m
EarningsUS$61.63m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)1.38
Gross Margin62.61%
Net Profit Margin12.01%
Debt/Equity Ratio67.1%

How did PCRX perform over the long term?

See historical performance and comparison

Valuation

Is Pacira BioSciences undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PCRX ($63.43) is trading below our estimate of fair value ($317.69)

Significantly Below Fair Value: PCRX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PCRX is poor value based on its PE Ratio (45.8x) compared to the US Pharmaceuticals industry average (23.3x).

PE vs Market: PCRX is poor value based on its PE Ratio (45.8x) compared to the US market (16.7x).


Price to Earnings Growth Ratio

PEG Ratio: PCRX is poor value based on its PEG Ratio (1.4x)


Price to Book Ratio

PB vs Industry: PCRX is overvalued based on its PB Ratio (3.9x) compared to the US Pharmaceuticals industry average (2.2x).


Future Growth

How is Pacira BioSciences forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

32.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PCRX's forecast earnings growth (32% per year) is above the savings rate (2%).

Earnings vs Market: PCRX's earnings (32% per year) are forecast to grow faster than the US market (13.1% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: PCRX's revenue (16.6% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: PCRX's revenue (16.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PCRX's Return on Equity is forecast to be high in 3 years time (23.6%)


Past Performance

How has Pacira BioSciences performed over the past 5 years?

78.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PCRX has high quality earnings.

Growing Profit Margin: PCRX's current net profit margins (12%) are lower than last year (30%).


Past Earnings Growth Analysis

Earnings Trend: PCRX has become profitable over the past 5 years, growing earnings by 78% per year.

Accelerating Growth: PCRX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PCRX had negative earnings growth (-51.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.2%).


Return on Equity

High ROE: PCRX's Return on Equity (8.6%) is considered low.


Financial Health

How is Pacira BioSciences's financial position?


Financial Position Analysis

Short Term Liabilities: PCRX's short term assets ($822.4M) exceed its short term liabilities ($225.8M).

Long Term Liabilities: PCRX's short term assets ($822.4M) exceed its long term liabilities ($411.6M).


Debt to Equity History and Analysis

Debt Level: PCRX has more cash than its total debt.

Reducing Debt: PCRX's debt to equity ratio has increased from 50.2% to 67.1% over the past 5 years.

Debt Coverage: PCRX's debt is well covered by operating cash flow (31%).

Interest Coverage: PCRX's interest payments on its debt are well covered by EBIT (4.3x coverage).


Balance Sheet


Dividend

What is Pacira BioSciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PCRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PCRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PCRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PCRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PCRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.7yrs

Average management tenure


CEO

Dave Stack (71 yo)

14.17yrs

Tenure

US$9,344,282

Compensation

Mr. David M. Stack, also known as Dave, has been the Chief Executive Officer of Pacira Pharmaceuticals Inc. Since November 2007, Mr. Stack serves as Director of CODA Biotherapeutics Inc. since December 202...


CEO Compensation Analysis

Compensation vs Market: Dave's total compensation ($USD9.34M) is above average for companies of similar size in the US market ($USD5.23M).

Compensation vs Earnings: Dave's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

Experienced Management: PCRX's management team is seasoned and experienced (5.7 years average tenure).


Board Members

Experienced Board: PCRX's board of directors are seasoned and experienced ( 10.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.5%.


Top Shareholders

Company Information

Pacira BioSciences, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Pacira BioSciences, Inc.
  • Ticker: PCRX
  • Exchange: NasdaqGS
  • Founded: 2006
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$2.825b
  • Shares outstanding: 44.54m
  • Website: https://www.pacira.com

Number of Employees


Location

  • Pacira BioSciences, Inc.
  • 5 Sylvan Way
  • Suite 300
  • Parsippany
  • New Jersey
  • 7054
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/21 23:33
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.